title: Highly active antiretroviral therapy and hospital readmission: comparison of a matched cohort.
abstract: BACKGROUND
  Despite the known efficacy of highly active antiretroviral therapy (HAART), a large proportion of potentially-eligible HIV-infected patients do not access, and may stand to benefit from this treatment. In order to quantify these benefits in terms of reductions in hospitalizations and hospitalization costs, we sought to determine the impact of HAART on hospital readmission among HIV-infected patients hospitalized at St. Paul's Hospital (SPH) in Vancouver, BC, Canada.
  
  
  METHODS
  All patients admitted to a specialized HIV/AIDS ward at SPH (Apr. 1997-Oct. 2002) were selected and classified as being on HAART or not on HAART based upon their initial admission. Patients were then matched by their propensity scores, which were calculated based on patients' sociodemographics such as age, gender, injection drug use (IDU) status, and AIDS indication, and followed up for one year. Multivariate logistic regression was used to estimate the difference in the odds of hospital readmission between patients on and not on HAART.
  
  
  RESULTS
  Out of a total 1084 patients admitted to the HIV/AIDS ward between 1997 and 2002, 662 were matched according to their propensity score; 331 patients each on and not on HAART. Multivariate logistic regression revealed that patients on HAART had lower odds of AIDS hospital readmission (OR, 0.61; 95% CI, 0.42-0.89) compared to patients not on HAART. Odds of readmission among patients on HAART were also significantly lower for non-IDU related readmission (OR, 0.73; 95% CI, 0.53-0.99) and overall readmission (OR, 0.72; 95% CI, 0.53-0.98).
  
  
  CONCLUSIONS
  Propensity score matching allowed us to reliably estimate the association between exposure (on or not on HAART) and outcome (readmitted to hospital). We found that HIV-infected patients who were potentially eligible for, but not on HAART had higher odds of being readmitted to hospital compared to those on HAART. Given the low level of uptake (31%) of HAART observed in our pre-matched hospitalized cohort, a large potential to achieve clinical benefits, reduce hospitalization costs and possibly slow disease progression from improved HAART uptake still exists.
authors.affiliation: Canadian HIV Trials Network, St, Paul's Hospital, Vancouver, BC, Canada. bnosyk@hivnet.ubc.ca
authors.forename: Bohdan
authors.initials: B
authors.lastname: Nosyk
authors.forename: Huiying
authors.initials: H
authors.lastname: Sun
authors.forename: Xin
authors.initials: X
authors.lastname: Li
authors.forename: Anita
authors.initials: A
authors.lastname: Palepu
authors.forename: Aslam H
authors.initials: AH
authors.lastname: Anis
mesh_terms: D000328:Adult; D023241:Antiretroviral Therapy, Highly Active / Q000191:economics*; D002170:Canada; D015331:Cohort Studies; D005260:Female; D005500:Follow-Up Studies; D015658:HIV Infections / Q000188:drug therapy / Q000191:economics*; D015497:HIV-1; D006760:Hospitalization / Q000191:economics / Q000706:statistics & numerical data*; D006801:Humans; D008297:Male; D008875:Middle Aged; D016017:Odds Ratio; D010359:Patient Readmission / Q000191:economics / Q000706:statistics & numerical data*